Modifying Antiretroviral Therapy in Virologically Suppressed HIV-Infected Patients

  • Author: José R. Arribas, MD (More Info)
  • Section Editor: Eric S. Daar, MD
  • Editors in Chief: Daniel R. Kuritzkes, MD; Joseph J. Eron, Jr., MD
  • Last Reviewed: 3/17/20 (What's New)


  • Results from the EASIER-ANRS 138 study[De Castro 2009] and other single-arm studies[Talbot 2009; Towner 2009] suggest that when substituting one antiretroviral agent with a low genetic barrier to resistance, such as enfuvirtide, for another, such as raltegravir, in virologically suppressed patients, the background regimen will most likely be potent enough to maintain virologic suppression

Action required